Please provide your email address to receive an email when new articles are posted on . Candesant Biomedical announced positive results from its pilot study on the targeted alkali thermolysis patch, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared Brella, a noninvasive, targeted alkali thermolysis product that treats primary axillary ...

The US Food and Drug Administration (FDA) today cleared the first patch to reduce excessive underarm sweating for adults with primary axillary hyperhidrosis. The single-use, disposable, ...

NASHVILLE, Tenn., March 18, 2023 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive treatments for ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...

QBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years of age and older with primary axillary hyperhidrosis, also known as excessive ...

Eun Lee, MD Key Takeaways Hyperhidrosis means sweating too much, even when you're not hot. There's no cure for hyperhidrosis, ...

- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial ...